107 related articles for article (PubMed ID: 19632790)
21. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
Vollmer CM; Eilber FC; Butterfield LH; Ribas A; Dissette VB; Koh A; Montejo LD; Lee MC; Andrews KJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 1999 Jul; 59(13):3064-7. PubMed ID: 10397245
[TBL] [Abstract][Full Text] [Related]
22. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
[TBL] [Abstract][Full Text] [Related]
23. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
24. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.
Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807
[TBL] [Abstract][Full Text] [Related]
27. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens.
Kondo E; Gryschok L; Schultze JL; von Bergwelt-Baildon MS
J Immunother; 2009; 32(2):157-60. PubMed ID: 19238014
[TBL] [Abstract][Full Text] [Related]
28. The role of CD40-CD40 ligand interactions in suppression of human B cell responsiveness by CD4+ T cells.
Hirohata S
Cell Immunol; 1997 Nov; 182(1):20-8. PubMed ID: 9427806
[TBL] [Abstract][Full Text] [Related]
29. Murine model of CD40-activation of B cells.
Liebig TM; Fiedler A; Klein-Gonzalez N; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
J Vis Exp; 2010 Mar; (37):. PubMed ID: 20208476
[TBL] [Abstract][Full Text] [Related]
30. Activated B cells mediate efficient expansion of rare antigen-specific T cells.
Zentz C; Wiesner M; Man S; Frankenberger B; Wollenberg B; Hillemanns P; Zeidler R; Hammerschmidt W; Moosmann A
Hum Immunol; 2007 Feb; 68(2):75-85. PubMed ID: 17321896
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J; Glennie MJ; Illidge TM
Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.
Si S; Sun Y; Li Z; Ge W; Zhang X; Hu P; Huang Y; Chen G; Song H; Huang Y; Ma B; Li X; Sui Y
Gene Ther; 2006 Nov; 13(22):1603-10. PubMed ID: 16855617
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
35. B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner.
RodrÃguez-Pinto D; Moreno J
Eur J Immunol; 2005 Apr; 35(4):1097-105. PubMed ID: 15756646
[TBL] [Abstract][Full Text] [Related]
36. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma.
Behboudi S; Boswell S; Williams R
Liver Int; 2010 Apr; 30(4):521-6. PubMed ID: 20040052
[TBL] [Abstract][Full Text] [Related]
37. CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response.
Jaiswal AI; Croft M
J Immunol; 1997 Sep; 159(5):2282-91. PubMed ID: 9278317
[TBL] [Abstract][Full Text] [Related]
38. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.
Butterfield LH; Ribas A; Meng WS; Dissette VB; Amarnani S; Vu HT; Seja E; Todd K; Glaspy JA; McBride WH; Economou JS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5902-8. PubMed ID: 14676113
[TBL] [Abstract][Full Text] [Related]
39. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction.
Klaus SJ; Pinchuk LM; Ochs HD; Law CL; Fanslow WC; Armitage RJ; Clark EA
J Immunol; 1994 Jun; 152(12):5643-52. PubMed ID: 7515910
[TBL] [Abstract][Full Text] [Related]
40. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
